The PPAR-platelet connection: Modulators of inflammation and potential cardiovascular effects

PPAR Research

Volumn 2008, Issue , 2008, Pages

  Spinelli, S L ^a   O'Brien, J J ^a   Bancos, S ^a   Lehmann, G M ^a   Springer, D L ^b   Blumberg, N ^a   Francis, C W ^a   Taubman, M B ^a   Phipps, R P ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ATHEROSCLEROSIS; CARDIOVASCULAR EFFECT; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIABETES MELLITUS; HEART INFARCTION; HUMAN; INFLAMMATION; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PLATELET MICROPARTICLE; REVIEW; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOSIS;

EID: 77954243510     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2008/328172     Document Type: Review

References (214)

1. D. L. Bhatt, P. G. Steg, E. M. Ohman, et al, "International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis," Journal of the American Medical Association, Vol. 295, no. 2, pp. 180-189, 2006.
2. A. J. Lusis, "Atherosclerosis," Nature, Vol. 407, no. 6801, pp. 233-241, 2000.
3. R. P. Phipps, "Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system," Proceedings of the National Academy of Sciences of the United States of America, Vol. 97, no. 13, pp. 6930-6932, 2000.
4. R. P. Phipps, L. Koumas, E. Leung, S. Y. Reddy, T. Blieden, and J. Kaufman, "The CD40-CD40 ligand system: a potential therapeutic target in atherosclerosis," Current Opinion in Investigational Drugs, Vol. 2, no. 6, pp. 773-777, 2001.
5. D. M. Ray, S. L. Spinelli, J. J. O'Brien, N. Blumberg, and R. P. Phipps, "Platelets as a novel target for PPARγ ligands: implications for inflammation, diabetes, and cardiovascular disease," BioDrugs, Vol. 20, no. 4, pp. 231-241, 2006.
6. R. Ross, "Atherosclerosis - an inflammatory disease," The New England Journal of Medicine, Vol. 340, no. 2, pp. 115-126, 1999.
7. S. Danese, C. de la Motte, A. Sturm, et al., "Platelets trigger a CD40-dependent inflammatory response in the microvas-culature of inflammatory bowel disease patients," Gastroenterology, Vol. 124, no. 5, pp. 1249-1264, 2003.
8. T Smith, G. Dhunnoo, I. Mohan, and V. Charlton-Menys, "A pilot study showing an association between platelet hyperactivity and the severity of peripheral arterial disease," Platelets, Vol. 18, no. 4, pp. 245-248, 2007.
9. K. T. Tan and G. Y. H. Lip, "The potential role of platelet microparticles in atherosclerosis," Thrombosis and Haemostasis, Vol. 94, no. 3, pp. 488-492, 2005.
10. A. I. Vinik, T. Erbas, T. S. Park, R. Nolan, and G. L. Pittenger, "Platelet dysfunction in type 2 diabetes," Diabetes Care, Vol. 24, no. 8, pp. 1476-1485, 2001.
11. Y. J. Lee, W. Jy, L. L. Horstman, et al, "Elevated platelet microparticles in transient ischemic attacks, lacunar infarcts, and multi-infarct dementias," Thrombosis Research, Vol. 72, no. 4, pp. 295-304, 1993.
12. S. Nomura, S. Uehata, S. Saito, K. Osumi, Y. Ozeki, and Y. Kimura, "Enzyme immunoassay detection of platelet-derived microparticles and RANTES in acute coronary syndrome," Thrombosis and Haemostasis, Vol. 89, no. 3, pp. 506-512, 2003.
13. F. Zeiger, S. Stephan, G. Hoheisel, D. Pfeiffer, C. Ruehlmann, and M. Koksch, "P-selectin expression, platelet aggregates, and platelet-derived microparticle formation are increased in peripheral arterial disease," Blood Coagulation and Fibrinolysis, Vol. 11, no. 8, pp. 723-728, 2000.
14. J. A. Coppinger, G. Cagney, S. Toomey, et al, "Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions," Blood, Vol. 103, no. 6, pp. 2096-2104, 2004.
15. A. García, S. P. Watson, R. A. Dwek, and N. Zitzmann, "Applying proteomics technology to platelet research," Mass Spectrometry Reviews, Vol. 24, no. 6, pp. 918-930, 2005.
16. J. P. McRedmond, S. D. Park, D. F. Reilly, et al, "Integration of proteomics and genomics in platelets: a profile of platelet proteins and platelet-specific genes," Molecular & Cellular Proteomics, Vol. 3, no. 2, pp. 133-144, 2004.
17. S. Kersten, B. Desvergne, and W. Wahli, "Roles of PPARs in health and disease," Nature, Vol. 405, no. 6785, pp. 421-424, 2000.
18. H. Inoue, X.-F. Jiang, T. Katayama, S. Osada, K. Umesono, and S. Namura, "Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor α in mice," Neuroscience Letters, Vol. 352, no. 3, pp. 203-206, 2003.
19. "Thiazolidinediones and cardiovascular disease," The Medical Letter on Drugs and Therapeutics, Vol. 49, no. 1265, pp. 57-58, 2007.
20. S. R. Patel, J. H. Hartwig, and J. E. Italiano Jr., "The biogenesis of platelets from megakaryocyte proplatelets," Journal of Clinical Investigation, Vol. 115, no. 12, pp. 3348-3354, 2005.
21. M. M. Denis, N. D. Tolley, M. Bunting, et al, "Escaping the nuclear confines: signal-dependent pre-mRNA splicing in anucleate platelets," Cell, Vol. 122, no. 3, pp. 379-391, 2005.
22. D. V. Gnatenko, J. J. Dunn, S. R. McCorkle, D. Weissmann, P. L. Perrotta, and W. F. Bahou, "Transcript profiling of human platelets using microarray and serial analysis of gene expression," Blood, Vol. 101, no. 6, pp. 2285-2293, 2003.
23. N. Kieffer, J. Guichard, J.-P. Farcet, W. Vainchenker, and J. Breton-Gorius, "Biosynthesis of major platelet proteins in human blood platelets," European Journal of Biochemistry, Vol. 164, no. 1, pp. 189-195, 1987.
24. A. S. Weyrich, D. A. Dixon, R. Pabla, et al, "Signal-dependent translation of a regulatory protein, Bcl-3, in activated human platelets," Proceedings of the National Academy of Sciences of the United States of America, Vol. 95, no. 10, pp. 5556-5561, 1998.
25. S. Lindemann, N. D. Tolley, D. A. Dixon, et al, "Activated platelets mediate inflammatory signaling by regulated interleukin 1β synthesis," Journal of Cell Biology, Vol. 154, no. 3, pp. 485-490, 2001.
26. H. Brogren, L. Karlsson, M. Andersson, L. Wang, D. Erlinge, and S. Jern, "Platelets synthesize large amounts of active plasminogen activator inhibitor 1," Blood, Vol. 104, no. 13, pp. 3943-3948, 2004.
27. M. Camera, M. Frigerio, V. Toschi, et al, "Platelet activation induces cell-surface immunoreactive tissue factor expression, which is modulated differently by antiplatelet drugs," Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 23, no. 9, pp. 1690-1696, 2003.
28. H. Schwertz, N. D. Tolley, J. M. Foulks, et al, "Signal-dependent splicing of tissue factor pre-mRNA modulates the thrombogenecity of human platelets," Journal of Experimental Medicine, Vol. 203, no. 11, pp. 2433-2440, 2006.
29. O. Panes, V. Matus, C. G. Sáez, T. Quiroga, J. Pereira, and D. Mezzano, "Human platelets synthesize and express functional tissue factor," Blood, Vol. 109, no. 12, pp. 5242-5250, 2007.
30. J. M. Cholette, N. Blumberg, R. P. Phipps, M. P. McDermott, K. F. Gettings, and N. P. Lerner, "Developmental changes in soluble CD40 ligand," Journal of Pediatrics. In Press.
31. P. Libby, "Vascular biology of atherosclerosis: overview and state of the art," The American Journal of Cardiology, Vol. 91, no. 3, supplement 1, pp. 3-6, 2003.
32. P. Aukrust, F. Müller, T. Ueland, et al, "Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes," Circulation, Vol. 100, no. 6, pp. 614-620, 1999.
33. F. Cipollone, A. Mezzetti, E. Porreca, et al, "Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy," Circulation, Vol. 106, no. 4, pp. 399-402, 2002.
34. C. Heeschen, S. Dimmeler, C. W. Hamm, et al, "Soluble CD40 ligand in acute coronary syndromes," The New England Journal of Medicine, Vol. 348, no. 12, pp. 1104-1111, 2003.
35. R. P. Phipps, J. Kaufman, and N. Blumberg, "Platelet derived CD154 (CD40 ligand) and febrile responses to transfusion," The Lancet, Vol. 357, no. 9273, pp. 2023-2024, 2001.
36. C. van Kooten and J. Banchereau, "CD40-CD40 ligand," Journal of Leukocyte Biology, Vol. 67, no. 1, pp. 2-17, 2000.
37. J. Kaufman, S. L. Spinelli, E. Schultz, N. Blumberg, and R. P. Phipps, "Release of biologically active CD154 during collection and storage of platelet concentrates prepared for transfusion," Journal of Thrombosis and Haemostasis, Vol. 5, no. 4, pp. 788-796, 2007.
38. C. Stumpf, C. Lehner, S. Eskafi, et al, "Enhanced levels of CD154 (CD40 ligand) on platelets in patients with chronic heart failure," European Journal of Heart Failure, Vol. 5, no. 5, pp. 629-637, 2003.
39. N. Varo, D. Vicent, P. Libby, et al, "Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones," Circulation, Vol. 107, no. 21, pp. 2664-2669, 2003.
40. R. J. Noelle, "CD40 and its ligand in host defense," Immunity, Vol. 4, no. 5, pp. 415-419, 1996.
41. 3 integrin-dependent mechanism," Nature Medicine, Vol. 8, no. 3, pp. 247-252, 2002.
42. S. A. Kliewer, B. M. Forman, B. Blumberg, et al, "Differential expression and activation of a family of murine peroxisome proliferator-activated receptors," Proceedings of the National Academy of Sciences of the United States of America, Vol. 91, no. 15, pp. 7355-7359, 1994.
43. 3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling," Proceedings of the National Academy of Sciences of the United States of America, Vol. 100, no. 21, pp. 12367-12371, 2003.
44. L. L. Horstman, W. Jy, J. J. Jimenez, C. Bidot, and Y. S. Ahn, "New horizons in the analysis of circulating cell-derived microparticles," Keio Journal of Medicine, Vol. 53, no. 4, pp. 210-230, 2004.
45. J. Simak and M. P. Gelderman, "Cell membrane microparticles in blood and blood products: potentially pathogenic agents and diagnostic markers," Transfusion Medicine Reviews, Vol. 20, no. 1, pp. 1-26, 2006.
46. A. P. Bode, H. Sandberg, F. A. Dombrose, and B. R. Lentz, "Association of factor V activity with membranous vesicles released from human platelets: requirement for platelet stimulation," Thrombosis Research, Vol. 39, no. 1, pp. 49-61, 1985.
47. P. Siljander, O. Carpen, and R. Lassila, "Platelet-derived microparticles associate with fibrin during thrombosis," Blood, Vol. 87, no. 11, pp. 4651-4663, 1996.
48. S. Nomura, N. N. Tandon, T. Nakamura, J. Cone, S. Fukuhara, and J. Kambayashi, "High-shear-stress-induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells," Atherosclerosis, Vol. 158, no. 2, pp. 277-287, 2001.
49. S. F. Mause, P. von Hundelshausen, A. Zernecke, R. R. Koenen, and C. Weber, "Platelet microparticles: a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium," Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 25, no. 7, pp. 1512-1518, 2005.
50. O. P. Barry, D. Praticò, R. C. Savani, and G. A. FitzGerald, "Modulation of monocyte-endothelial cell interactions by platelet microparticles," Journal of Clinical Investigation, Vol. 102, no. 1, pp. 136-144, 1998.
51. T. Scholz, U. Temmler, S. Krause, S. Heptinstall, and W. Lösche, "Transfer of tissue factor from platelets to monocytes: role of platelet-derived microvesicles and CD62P," Thrombosis and Haemostasis, Vol. 88, no. 6, pp. 1033-1038, 2002.
52. M. J. VanWijk, E. VanBavel, A. Sturk, and R. Nieuwland, "Microparticles in cardiovascular diseases," Cardiovascular Research, Vol. 59, no. 2, pp. 277-287, 2003.
53. M. Diamant, R. Nieuwland, R. F. Pablo, A. Sturk, J. W. A. Smit, and J. K. Radder, "Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus," Circulation, Vol. 106, no. 19, pp. 2442-2447, 2002.
54. A. Janowska-Wieczorek, M. Majka, J. Kijowski, et al, "Platelet-derived microparticles bind to hematopoietic stem/progenitor cells and enhance their engraftment," Blood, Vol. 98, no. 10, pp. 3143-3149, 2001.
55. H. Duez, J.-C. Fruchart, and B. Staels, "PPARs in inflammation, atherosclerosis and thrombosis," Journal of Cardiovascular Risk, Vol. 8, no. 4, pp. 187-194, 2001.
56. J. Padilla, K. Kaur, S. G. Harris, and R. P. Phipps, "PPARγ-mediated regulation of normal and malignant B lineage cells," Annals of the New York Academy of Sciences, Vol. 905, pp. 97-109, 2000.
57. I. Issemann and S. Green, "Cloning of novel members of the steroid hormone receptor superfamily," Journal of Steroid Biochemistry and Molecular Biology, Vol. 40, no. 1-3, pp. 263-269, 1991.
58. O. Braissant, F. Foufelle, C. Scotto, M. Dauça, and W. Wahli, "Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat," Endocrinology, Vol. 137, no. 1, pp. 354-366, 1996.
59. S. G. Harris and R. P. Phipps, "The nuclear receptor PPAR γ is expressed by mouse T lymphocytes and PPAR γ agonists induce apoptosis," European Journal of Immunology, Vol. 31, no. 4, pp. 1098-1105, 2001.
60. D. M. Ray, S. H. Bernstein, and R. P. Phipps, "Human multiple myeloma cells express peroxisome proliferator-activated receptor γ and undergo apoptosis upon exposure to PPARy ligands," Clinical Immunology, Vol. 113, no. 2, pp. 203-213, 2004.
61. D. Auboeuf, J. Rieusset, L. Fajas, et al, "Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-α in humans: no alteration in adipose tissue of obese and NIDDM patients," Diabetes, Vol. 46, no. 8, pp. 1319-1327, 1997.
62. U. Seedorf and J. Aberle, "Emerging roles of PPARδ in metabolism," Biochimica et Biophysica Acta, Vol. 1771, no. 9, pp. 1125-1131, 2007.
63. F. Akbiyik, D. M. Ray, K. F. Gettings, N. Blumberg, C. W. Francis, and R. P. Phipps, "Human bone marrow megakaryocytes and platelets express PPARy, and PPARy agonists blunt platelet release of CD40 ligand and thromboxanes," Blood, Vol. 104, no. 5, pp. 1361-1368, 2004.
64. F. Y. Ali, S. J. Davidson, L. A. Moraes, et al, "Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARβ," The FASEB Journal, Vol. 20, no. 2, pp. 326-328, 2006.
65. S. A. Kliewer, K. Umesono, D. J. Noonan, R. A. Heyman, and R. M. Evans, "Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors," Nature, Vol. 358, no. 6389, pp. 771-774, 1992.
66. A. I. Shulman and D. J. Mangelsdorf, "Retinoid X receptor heterodimers in the metabolic syndrome," The New England Journal of Medicine, Vol. 353, no. 6, pp. 604-615, 2005.
67. J. Plutzky, "Inflammation in atherosclerosis and diabetes mellitus," Reviews in Endocrine and Metabolic Disorders, Vol. 5, no. 3, pp. 255-259, 2004.
68. N. Marx, H. Duez, J.-C. Fruchart, and B. Staels, "Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells," Circulation Research, Vol. 94, no. 9, pp. 1168-1178, 2004.
69. G. Rizzo and S. Fiorucci, "PPARs and other nuclear receptors in inflammation," Current Opinion in Pharmacology, Vol. 6, no. 4, pp. 421-427, 2006.
70. T. Sher, H. F. Yi, O. W. McBride, and F. J. Gonzalez, "cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor," Biochemistry, Vol. 32, no. 21, pp. 5598-5604, 1993.
71. N. Sambandam, D. Morabito, C. Wagg, B. N. Finck, D. P. Kelly, and G. D. Lopaschuk, "Chronic activation of PPARα is detrimental to cardiac recovery after ischemia," American Journal of Physiology, Vol. 290, no. 1, pp. H87-H95, 2006.
72. T. H. Thatcher, P. J. Sime, and R. K. Barth, "Sensitivity to bleomycin-induced lung injury is not moderated by an antigen-limited T-cell repertoire," Experimental Lung Research, Vol. 31, no. 7, pp. 685-700, 2005.
73. H. F. Lakatos, T. H. Thatcher, R. M. Kottmann, T. M. Garcia, R. P. Phipps, and P. J. Sime, "The role of PPARs in lung fibrosis," PPAR Research, Vol. 2007, Article ID 71323, 10 pages, 2007.
74. J. Auwerx, K. Schoonjans, J.-C. Fruchart, and B. Staels, "Regulation of triglyceride metabolism by PPARs: fibrates andthi-azolidinediones have distinct effects," Journal of atherosclerosis and thrombosis, Vol. 3, no. 2, pp. 81-89, 1996.
75. J. D. Brown and J. Plutzky, "Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets," Circulation, Vol. 115, no. 4, pp. 518-533, 2007.
76. Y.-X. Wang, C.-H. Lee, S. Tiep, et al, "Peroxisome-proliferator-activated receptor S activates fat metabolism to prevent obesity," Cell, Vol. 113, no. 2, pp. 159-170, 2003.
77. G. D. Barish, V. A. Narkar, and R. M. Evans, "PPARδ: a dagger in the heart of the metabolic syndrome," Journal of Clinical Investigation, Vol. 116, no. 3, pp. 590-597, 2006.
78. C.-H. Lee, A. Chawla, N. Urbiztondo, D. Liao, W. A. Boisvert, and R. M. Evans, "Transcriptional repression of atherogenic inflammation: modulation by PPARδ," Science, Vol. 302, no. 5644, pp. 453-457, 2003.
79. H. Lim and S. K. Dey, "Minireview: a novel pathway of prostacyclin signaling - hanging out with nuclear receptors," Endocrinology, Vol. 143, no. 9, pp. 3207-3210, 2002.
80. B. M. Forman, J. Chen, and R. M. Evans, "Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and 5," Proceedings of the National Academy of Sciences of the United States of America, Vol. 94, no. 9, pp. 4312-4317, 1997.
81. G. Anfossi, P. Massucco, E. Mularoni, F. Cavalot, L. Mattiello, and M. Trovati, "Organic nitrates and compounds that increase intraplatelet cyclic guanosine monophosphate (cGMP) levels enhance the antiaggregating effects of the stable prostacyclin analogue iloprost," Prostaglandins Leukotrienes and Essential Fatty Acids, Vol. 49, no. 5, pp. 839-845, 1993.
82. R. J. Gryglewski, "Interactions between nitric oxide and prostacyclin," Seminars in Thrombosis and Hemostasis, Vol. 19, no. 2, pp. 158-166, 1993.
83. P. S. Macdonald, M. A. Read, and G. J. Dusting, "Synergistic inhibition of platelet aggregation by endothelium-derived relaxing factor and prostacyclin," Thrombosis Research, Vol. 49, no. 5, pp. 437-449, 1988.
84. M. W. Radomski, R. M. Palmer, and S. Moncada, "The antiaggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide," British Journal of Pharmacology, Vol. 92, no. 3, pp. 639-646, 1987.
85. M. Spiecker, H. Darius, and J. Meyer, "Synergistic platelet antiaggregatory effects of the adenylate cyclase activator iloprost and the guanylate cyclase activating agent SIN-1 in vivo," Thrombosis Research, Vol. 70, no. 5, pp. 405-415, 1993.
86. P. S. Lidbury, E. Antunes, G. de Nucci, and J. R. Vane, "Interactions of iloprost and sodium nitroprusside on vascular smooth muscle and platelet aggregation," British Journal of Pharmacology, Vol. 98, no. 4, pp. 1275-1280, 1989.
87. R. Katzenschlager, K. Weiss, W. Rogatti, B. A. Peskar, and H. Sinzinger, "Synergism between PGE1-metabolites (13,14-dihydro-prostaglandin E1, 15-keto prostaglandin E1, 15-keto-13,14-Dihydro-prostaglandin E1) and nitric oxide (NO) on platelet aggregation," Prostaglandins Leukotrienes and Essential Fatty Acids, Vol. 45, no. 3, pp. 207-210, 1992.
88. R. Katzenschlager, K. Weiss, W. Rogatti, M. Stelzeneder, and H. Sinzinger, "Interaction between prostaglandin E1 and nitric oxide (NO)," Thrombosis Research, Vol. 62, no. 4, pp. 299-304, 1991.
89. F. Y Ali, K. Egan, G. A. FitzGerald, et al, "Role of prostacyclin versus peroxisome proliferator-activated receptor β receptors in prostacyclin sensing by lung fibroblasts," American Journal of Respiratory Cell and Molecular Biology, Vol. 34, no. 2, pp. 242-246, 2006.
90. T. M. Willson, P. J. Brown, D. D. Sternbach, and B. R. Henke, "The PPARs: from orphan receptors to drug discovery," Journal of Medicinal Chemistry, Vol. 43, no. 4, pp. 527-550, 2000.
91. J. Padilla, E. Leung, and R. P. Phipps, "Human B lymphocytes and B lymphomas express PPAR-γ and are killed by PPAR-γ agonists," Clinical Immunology, Vol. 103, no. 1, pp. 22-33, 2002.
92. D. Kelly, J. I. Campbell, T. P. King, et al, "Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shutting of PPAR-y and ReIA," Nature Immunology, Vol. 5, no. 1, pp. 104-112, 2004.
93. Y. Zhu, C. Qi, J. R. Korenberg, et al, "Structural organization of mouse peroxisome proliferator-activated receptor γ (mPPARγ) gene: alternative promoter use and different splicing yield two mPPARy isoforms," Proceedings of the National Academy of Sciences of the United States of America, Vol. 92, no. 17, pp. 7921-7925, 1995.
94. L. Fajas, D. Auboeuf, E. Raspé, et al, "The organization, promoter analysis, and expression of the human PPARy gene," Journal of Biological Chemistry, Vol. 272, no. 30, pp. 18779-18789, 1997.
95. M. Ricote, J. Huang, L. Fajas, et al, "Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein," Proceedings of the National Academy of Sciences of the United States of America, Vol. 95, no. 13, pp. 7614-7619, 1998.
96. K. Iijima, M. Yoshizumi, J. Ako, et al, "Expression of peroxisome proliferator-activated receptor γ (PPARγ) in rat aortic smooth muscle cells," Biochemical and Biophysical Research Communications, Vol. 247, no. 2, pp. 353-356, 1998.
97. A. Nencioni, F. Grünebach, A. Zobywlaski, C. Denzlinger, W. Brugger, and P. Brossart, "Dendritic cell immunogenicity is regulated by peroxisome proliferator-activated receptor y," Journal of Immunology, Vol. 169, no. 3, pp. 1228-1235, 2002.
98. M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, "The peroxisome proliferator-activated receptor-y is a negative regulator of macrophage activation," Nature, Vol. 391, no. 6662, pp. 79-82, 1998.
99. L. Michalik, B. Desvergne, and W. Wahli, "Peroxisome-proliferator-activated receptors and cancers: complex stories," Nature Reviews Cancer, Vol. 4, no. 1, pp. 61-70, 2004.
100. S. G. Harris, J. Padilla, L. Koumas, D. M. Ray, and R. P. Phipps, "Prostaglandins as modulators of immunity," Trends in Immunology, Vol. 23, no. 3, pp. 144-150, 2002.
101. A. von Knethen, M. Soller, N. Tzieply, et al, "PPARy1 attenuates cytosol to membrane translocation of PKCα to desensitize monocytes/macrophages," Journal of Cell Biology, Vol. 176, no. 5, pp. 681-694, 2007.
102. S. W. Chung, B. Y Kang, S. H. Kim, et al, "Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-y and nuclear factor-κB," Journal of Biological Chemistry, Vol. 275, no. 42, pp. 32681-32687, 2000.
103. F. Chen, V. Castranova, X. Shi, and L. M. Demers, "New insights into the role of nuclear factor-κB, a ubiquitous transcription factor in the initiation of diseases," Clinical Chemistry, Vol. 45, no. 1, pp. 7-17, 1999.
104. L. A. Moraes, K. E. Swales, J. A. Wray, et al, "Nongenomic signaling of the retinoid X receptor through binding and in-hibiting Gq in human platelets," Blood, Vol. 109, no. 9, pp. 3741-3744, 2007.
105. D. M. Ray, S. L. Spinelli, S. J. Pollock, et al, "Peroxisome proliferator-activated receptor γ and the retinoid X receptor transcription factors are released from activated human platelets and are shed in microparticles," Thrombosis and Haemostasis, Vol. 101, 2008.
106. V. Pasceri, H. D. Wu, J. T. Willerson, and E. T. H. Yeh, "Modulation of vascular inflammation in vitro and in vivo by per-oxisome proliferator-activated receptor-γ activators," Circulation, Vol. 101, no. 3, pp. 235-238, 2000.
107. K. Goya, S. Sumitani, M. Otsuki, et al, "The thiazolidine-dione drug troglitazone up-regulates nitric oxide synthase expression in vascular endothelial cells," Journal of Diabetes and its Complications, Vol. 20, no. 5, pp. 336-342, 2006.
108. G. Anfossi and M. Trovati, "Pathophysiology of platelet resistance to anti-aggregating agents in insulin resistance and type 2 diabetes: implications for anti-aggregating therapy," Cardiovascular and Hematological Agents in Medicinal Chemistry, Vol. 4, no. 2, pp. 111-128, 2006.
109. I. Juhan-Vague, P. E. Morange, and M.-C. Alessi, "The insulin resistance syndrome: implications for thrombosis and cardiovascular disease," Pathophysiology of Haemostasis and Thrombosis, Vol. 32, no. 5-6, pp. 269-273, 2002.
110. D. J. Schneider, "Abnormalities of coagulation, platelet function, and fibrinolysis associated with syndromes of insulin resistance," Coronary Artery Disease, Vol. 16, no. 8, pp. 473-476, 2005.
111. M. Trovati and G. Anfossi, "Mechanisms involved in platelet hyperactivation and platelet-endothelium interrelationships in diabetes mellitus," Current Diabetes Reports, Vol. 2, no. 4, pp. 316-322, 2002.
112. M. Trovati and G. Anfossi, "Influence of insulin and of insulin resistance on platelet and vascular smooth muscle cell function," Journal of Diabetes and Its Complications, Vol. 16, no. 1, pp. 35-40, 2002.
113. W. R. Oliver Jr., J. L. Shenk, M. R. Snaith, et al., "A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport," Proceedings of the National Academy of Sciences of the United States of America, Vol. 98, no. 9, pp. 5306-5311, 2001.
114. P. Libby, P. M. Ridker, and A. Maseri, "Inflammation and atherosclerosis," Circulation, Vol. 105, no. 9, pp. 1135-1143, 2002.
115. S. Lindemann, B. Krämer, P. Seizer, and M. Gawaz, "Platelets, inflammation and atherosclerosis," Journal of Thrombosis and Haemostasis, Vol. 5, supplement 1, pp. 203-211, 2007.
116. Z. M. Dong, S. M. Chapman, A. A. Brown, P. S. Frenette, R. O. Hynes, and D. D. Wagner, "The combined role of P- and E-selectins in atherosclerosis," Journal of Clinical Investigation, Vol. 102, no. 1, pp. 145-152, 1998.
117. Y. Huo, A. Schober, S. B. Forlow, et al, "Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E," Nature Medicine, Vol. 9, no. 1, pp. 61-67, 2002.
118. + progenitor cells into foam cells and endothelial cells," The FASEB Journal, Vol. 20, no. 14, pp. 2559-2561, 2006.
119. S. Massberg, K. Brand, S. Grüner, et al, "A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation," Journal of Experimental Medicine, Vol. 196, no. 7, pp. 887-896, 2002.
120. S. Massberg, K. Schürzinger, M. Lorenz, et al, "Platelet adhesion via glycoprotein IIb integrin is critical for athero-progression and focal cerebral ischemia: an in vivo study in mice lacking glycoprotein IIb," Circulation, Vol. 112, no. 8, pp. 1180-1188, 2005.
121. 3 integrin, and GPIbα," Journal of Experimental Medicine, Vol. 187, no. 3, pp. 329-339, 1998.
122. 3) mediates platelet adhesion to the luminal aspect of endothelial cells: implications for reperfusion in acute myocardial infarction," Circulation, Vol. 96, no. 6, pp. 1809-1818, 1997.
123. M. Gawaz, F.-J. Neumann, I. Ott, A. Schiessler, and A. Schömig, "Platelet function in acute myocardial infarction treated with direct angioplasty," Circulation, Vol. 93, no. 2, pp. 229-237, 1996.
124. H. Langer, A. E. May, K. Daub, et al, "Adherent platelets recruit and induce differentiation of murine embryonic endothelial progenitor cells to mature endothelial cells in vitro," Circulation Research, Vol. 98, no. 2, pp. e2-e10, 2006.
125. D. M. Jans, W. Martinet, M. Fillet, et al, "Effect of nonsteroidal anti-inflammatory drugs on amyloid-β formation and macrophage activation after platelet phagocytosis," Journal of Cardiovascular Pharmacology, Vol. 43, no. 3, pp. 462-470, 2004.
126. G. R. Y. De Meyer, D. M. M. De Cleen, S. Cooper, et al., "Platelet phagocytosis and processing of β-amyloid precursor protein as a mechanism of macrophage activation in atherosclerosis," Circulation Research, Vol. 90, no. 11, pp. 1197-1204, 2002.
127. T. Nassar, B. S. Sachais, S. Akkawi, et al, "Platelet factor 4 enhances the binding of oxidized low-density lipoprotein to vascular wall cells," Journal of Biological Chemistry, Vol. 278, no. 8, pp. 6187-6193, 2003.
128. M. Gawaz, K. Brand, T. Dickfeld, et al, "Platelets induce alterations of chemotactic and adhesive properties of endothelial cells mediated through an interleukin-1-dependent mechanism. Implications for atherogenesis," Atherosclerosis, Vol. 148, no. 1, pp. 75-85, 2000.
129. P. von Hundelshausen, K. S. Weber, Y. Huo, et al, "RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium," Circulation, Vol. 103, no. 13, pp. 1772-1777, 2001.
130. C. Fernandez-Patron, M. A. Martinez-Cuesta, E. Salas, et al, "Differential regulation of platelet aggregation by matrix metalloproteinases-9 and -2," Thrombosis and Haemostasis, Vol. 82, no. 6, pp. 1730-1735, 1999.
131. G. Sawicki, E. Salas, J. Murat, H. Miszta-Lane, and M. W. Radomski, "Release of gelatinase A during platelet activation mediates aggregation," Nature, Vol. 386, no. 6625, pp. 616-619, 1997.
132. 3) on platelets upregulates CD40L and triggers CD40L-dependent matrix degradation by endothelial cells," Circulation, Vol. 106, no. 16, pp. 2111-2117, 2002.
133. S. Bellosta, D. Via, M. Canavesi, et al, "HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages," Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 18, no. 11, pp. 1671-1678, 1998.
134. S. W. Galt, S. Lindemann, D. Medd, et al, "Differential regulation of matrix metalloproteinase-9 by monocytes adherent to collagen and platelets," Circulation Research, Vol. 89, no. 6, pp. 509-516, 2001.
135. N. A. Turner, D. J. O'Regan, S. G. Ball, and K. E. Porter, "Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels," The FASEB Journal, Vol. 19, no. 7, pp. 804-806, 2005.
136. B. Wong, W. C. Lumma, A. M. Smith, J. T. Sisko, S. D. Wright, and T.-Q. Cai, "Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranyl-geranylation," Journal of Leukocyte Biology, Vol. 69, no. 6, pp. 959-962, 2001.
137. S. Toomey, B. Harhen, H. M. Roche, D. Fitzgerald, and O. Belton, "Profound resolution of early atherosclerosis with conjugated linoleic acid," Atherosclerosis, Vol. 187, no. 1, pp. 40-49, 2006.
138. A. C. Li, C. J. Binder, A. Gutierrez, et al, "Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and γ," Journal of Clinical Investigation, Vol. 114, no. 11, pp. 1564-1576, 2004.
139. Z. Chen, S. Ishibashi, S. Perrey, et al, "Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL," Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 21, no. 3, pp. 372-377, 2001.
140. A. C. Li, K. K. Brown, M. J. Silvestre, T. M. Willson, W. Palinski, and C. K. Glass, "Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice," Journal of Clinical Investigation, Vol. 106, no. 4, pp. 523-531, 2000.
141. S. Cuzzocrea, B. Pisano, L. Dugo, et al, "Rosiglitazone, alig-and of the peroxisome proliferator-activated receptor-γ, reduces acute pancreatitis induced by cerulein," Intensive Care Medicine, Vol. 30, no. 5, pp. 951-956, 2004.
142. H. Shu, B. Wong, G. Zhou, et al, "Activation of PPARα or γ reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells," Biochemical and Biophysical Research Communications, Vol. 267, no. 1, pp. 345-349, 2000.
143. J. S. Sidhu, D. Cowan, J. A. Tooze, and J.-C. Kaski, "Peroxisome proliferator-activated receptor-y agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease," American Heart Journal, Vol. 147, no. 6, pp. 1032-1037, 2004.
144. F. F. Samaha, P. O. Szapary, N. Iqbal, et al, "Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome," Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 26, no. 3, pp. 624-630, 2006.
145. M. D. Leibowitz, C. Fiévet, N. Hennuyer, et al, "Activation of PPARδ alters lipid metabolism in db/db mice," FEBS Letters, Vol. 473, no. 3, pp. 333-336, 2000.
146. J. N. van der Veen, J. K. Kruit, R. Havinga, et al., "Reduced cholesterol absorption upon PPARδ activation coincides with decreased intestinal expression of NPC1L1," Journal of Lipid Research, Vol. 46, no. 3, pp. 526-534, 2005.
147. A. Gallino, A. Haeberli, H. R. Baur, and P. W. Straub, "Fibrin formation and platelet aggregation in patients with severe coronary artery disease: relationship with the degree of myocardial ischemia," Circulation, Vol. 72, no. 1, pp. 27-30, 1985.
148. B. Ashby, J. L. Daniel, and J. B. Smith, "Mechanisms of platelet activation and inhibition," Hematology/Oncology Clinics of North America, Vol. 4, no. 1, pp. 1-26, 1990.
149. T. Ishizuka, S. Itaya, H. Wada, et al, "Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism," Diabetes, Vol. 47, no. 9, pp. 1494-1500, 1998.
150. M. Lorenz, S. Wessler, E. Follmann, et al, "A constituent of green tea, epigallocatechin-3-gallate, activates endothelial nitric oxide synthase by a phosphatidylinositol-3-OH-kinase-, cAMP-dependent protein kinase-, and Akt-dependent pathway and leads to endothelial-dependent vasorelaxation," Journal of Biological Chemistry, Vol. 279, no. 7, pp. 6190-6195, 2004.
151. D. Li, K. Chen, N. Sinha, et al, "The effects of PPAR-γ lig-and pioglitazone on platelet aggregation and arterial thrombus formation," Cardiovascular Research, Vol. 65, no. 4, pp. 907-912, 2005.
152. H. Kanehara, G. Tohda, K. Oida, J. Suzuki, H. Ishii, and I. Miyamori, "Thrombomodulin expression by THP-1 but not by vascular endothelial cells is upregulated by pioglitazone," Thrombosis Research, Vol. 108, no. 4, pp. 227-234, 2002.
153. D. S. Calnek, L. Mazzella, S. Roser, J. Roman, and C. M. Hart, "Peroxisome proliferator-activated receptor γ ligands increase release of nitric oxide from endothelial cells," Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 23, no. 1, pp. 52-57, 2003.
154. D.-H. Cho, Y. J. Choi, S. A. Jo, and I. Jo, "Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: evidence for involvement of peroxisome proliferator-activated receptor (PPAR) γ-dependent and PPARγ-independent signaling pathways," Journal of Biological Chemistry, Vol. 279, no. 4, pp. 2499-2506, 2004.
155. H. Takano, T. Nagai, M. Asakawa, et al, "Peroxi-some proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-α expression in neonatal rat cardiac myocytes," Circulation Research, Vol. 87, no. 7, pp. 596-602, 2000.
156. T.-L. Yue, J. Chen, W. Bao, et al, "In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone," Circulation, Vol. 104, no. 21, pp. 2588-2594, 2001.
157. J. E. Jordan, Z.-Q. Zhao, and J. Vinten-Johansen, "The role of neutrophils in myocardial ischemia-reperfusion injury," Cardiovascular Research, Vol. 43, no. 4, pp. 860-878, 1999.
158. M. Ricote, J. T. Huang, J. S. Welch, and C. K. Glass, "The per-oxisome proliferator-activated receptorγ (PPARγ) as a regulator of monocyte/macrophage function," Journal of Leukocyte Biology, Vol. 66, no. 5, pp. 733-739, 1999.
159. S.S. Huang, M. C. Tsai, C. L. Chih, L.M. Hung, and S. K. Tsai, "Resveratrol reduction of infarct size in Long-Evans rats subjected to focal cerebral ischemia," Life Sciences, Vol. 69, no. 9, pp. 1057-1065, 2001.
160. D. L. Feinstein, "Therapeutic potential of peroxisome proliferator-activated receptor agonists for neurological disease," Diabetes Technology & Therapeutics, Vol. 5, no. 1, pp. 67-73, 2003.
161. R. Bordet, T. Ouk, O. Petrault, et al, "PPAR: a new pharmacological target for neuroprotection in stroke and neurode-generative diseases," Biochemical Society Transactions, Vol. 34, part 6, pp. 1341-1346, 2006.
162. S. Rios, "Relationship between obesity and the increased risk of major complications in non-insulin-dependent diabetes mellitus," European Journal of Clinical Investigation, Vol. 28, supplement 2, pp. 14-18, 1998.
163. R. J. Gryglewski, R. M. Botting, and J. R. Vane, "Mediators produced by the endothelial cell," Hypertension, Vol. 12, no. 6, pp. 530-548, 1988.
164. G. Anfossi, E. M. Mularoni, S. Burzacca, et al, "Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM," Diabetes Care, Vol. 21, no. 1, pp. 121-126, 1998.
165. G. Anfossi, I. Russo, P. Massucco, et al, "Impaired synthesis and action of antiaggregating cyclic nucleotides in platelets from obese subjects: possible role in platelet hyperactivation in obesity," European Journal of Clinical Investigation, Vol. 34, no. 7, pp. 482-489, 2004.
166. T. Akai, K. Naka, K. Okuda, T. Takemura, and S. Fujii, "Decreased sensitivity of platelets to prostacyclin in patients with diabetes mellitus," Hormone and Metabolic Research, Vol. 15, no. 11, pp. 523-526, 1983.
167. C. Falcon, G. Pfliegler, H. Deckmyn, and J. Vermylen, "The platelet insulin receptor: detection, partial characterizaztion, and search for a function," Biochemical and Biophysical Research Communications, Vol. 157, no. 3, pp. 1190-1196, 1988.
168. M. Trovati, G. Anfossi, F. Cavalot, P. Massucco, E. Mularoni, and G. Emanuelli, "Insulin directly reduces platelet sensitivity to aggregating agents. Studies in vitro and in vivo," Diabetes, Vol. 37, no. 6, pp. 780-786, 1988.
169. M. Udvardy, G. Pfliegler, and K. Rak, "Platelet insulin receptor determination in non-insulin dependent diabetes mellitus," Cellular and Molecular Life Sciences, Vol. 41, no. 3, pp. 422-423, 1985.
170. N. N. Kahn, H. S. Mueller, and A. K. Sinha, "Restoration by insulin of impaired prostaglandin E1/I2 receptor activity of platelets in acute ischemic heart disease," Circulation Research, Vol. 68, no. 1, pp. 245-254, 1991.
171. B. Lipinski, "Pathophysiology of oxidative stress in diabetes mellitus," Journal of Diabetes and its Complications, Vol. 15, no. 4, pp. 203-210, 2001.
172. J. V. Hunt, C. C. Smith, and S. P. Wolff, "Autoxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose," Diabetes, Vol. 39, no. 11, pp. 1420-1424, 1990.
173. W. E. Lands and R. J. Kulmacz, "The regulation of the biosynthesis of prostaglandins and leukotrienes," Progress in Lipid Research, Vol. 25, no. 1-4, pp. 105-109, 1986.
174. M. Lagarde, "Metabolism of fatty acids by platelets and the functions of various metabolites in mediating platelet function," Progress in Lipid Research, Vol. 27, no. 2, pp. 135-152, 1988.
175. E. Véricel, C. Januel, M. Carreras, P. Moulin, and M. Lagarde, "Diabetic patients without vascular complications display enhanced basal platelet activation and decreased antioxidant status," Diabetes, Vol. 53, no. 4, pp. 1046-1051, 2004.
176. C. Calzada, E. Véricel, B. Mitel, L. Coulon, and M. Lagarde, "12(S)-hydroperoxy-eicosatetraenoic acid increases arachidonic acid availability in collagen-primed platelets," Journal of Lipid Research, Vol. 42, no. 9, pp. 1467-1473, 2001.
177. D. Tschoepe, U. Rauch, and B. Schwippert, "Platelet-leukocyte-cross-talk in diabetes mellitus," Hormone and Metabolic Research, Vol. 29, no. 12, pp. 631-635, 1997.
178. H. Lee, R. C. Paton, P. Passa, and J. P. Caen, "Fibrinogen binding and ADP-induced aggregation in platelets from diabetic subjects," Thrombosis Research, Vol. 24, no. 1-2, pp. 143-150, 1981.
179. P. V. Halushka, R. C. Rogers, C. B. Loadholt, and J. A. Colwell, "Increased platelet thromboxane synthesis in diabetes mellitus," Journal of Laboratory and Clinical Medicine, Vol. 97, no. 1, pp. 87-96, 1981.
180. R. K. Mayfield, P. V. Halushka, H. J. Wohltmann, et al, "Platelet function during continuous insulin infusion treatment in insulin-dependent diabetic patients," Diabetes, Vol. 34, no. 11, pp. 1127-1133, 1985.
181. N. Marx, A. Imhof, J. Froehlich, et al, "Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease," Circulation, Vol. 107, no. 15, pp. 1954-1957, 2003.
182. R. Stienstra, C. Duval, M. Müller, and S. Kersten, "PPARs, obesity, and inflammation," PPAR Research, Vol. 2007, Article ID 95974, 10 pages, 2007.
183. P. Trayhurn and I. S. Wood, "Signalling role of adipose tissue: adipokines and inflammation in obesity," Biochemical Society Transactions, Vol. 33, part 5, pp. 1078-1081, 2005.
184. Y.-H. Yu and H. N. Ginsberg, "Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue," Circulation Research, Vol. 96, no. 10, pp. 1042-1052, 2005.
185. R. Jones, "Nonsteroidal anti-inflammatory drug prescribing: past, present, and future," The American Journal of Medicine, Vol. 110, no. 1, supplement 1, pp. S4-S7, 2001.
186. G. J. Hankey and J. W. Eikelboom, "Aspirin resistance," British Medical Journal, Vol. 328, no. 7438, pp. 477-479, 2004.
187. J. A. Cambria-Kiely and P. J. Gandhi, "Aspirin resistance and genetic polymorphisms," Journal of Thrombosis and Thrombolysis, Vol. 14, no. 1, pp. 51-58, 2002.
188. A. Szczeklik, J. Musiał, A. Undas, and M. Sanak, "Aspirin resistance," Journal of Thrombosis and Haemostasis, Vol. 3, no. 8, pp. 1655-1662, 2005.
189. D. M. Becker, J. Segal, D. Vaidya, et al, "Sex differences in platelet reactivity and response to low-dose aspirin therapy," Journal of the American Medical Association, Vol. 295, no. 12, pp. 1420-1427, 2006.
190. D. L. Bhatt, K. A. A. Fox, W. Hacke, et al, "Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events," The New England Journal of Medicine, Vol. 354, no. 16, pp. 1706-1717, 2006.
191. D. L. Bhatt and E. J. Topol, "Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance (CHARISMA) trial," American Heart Journal, Vol. 148, no. 2, pp. 263-268, 2004.
192. C. L. Bennett, J. M. Connors, J. M. Carwile, et al, "Thrombotic thrombocytopenic purpura associated with clopidogrel," The New England Journal of Medicine, Vol. 342, no. 24, pp. 1773-1777, 2000.
193. S. R. Steinhubl, W. A. Tan, J. M. Foody, and E. J. Topol, "Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting," Journal of the American Medical Association, Vol. 281, no. 9, pp. 806-810, 1999.
194. D. P. Chew and D. L. Bhatt, "Oral glycoprotein IIb/IIIa antagonists in coronary artery disease," Current Cardiology Reports, Vol. 3, no. 1, pp. 63-71, 2001.
195. D. P. Chew, D. L. Bhatt, S. Sapp, and E. J. Topol, "Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials," Circulation, Vol. 103, no. 2, pp. 201-206, 2001.
196. E. S. Tai, D. Collins, S. J. Robins, et al, "The L162V polymorphism at the peroxisome proliferator activated receptor α locus modulates the risk of cardiovascular events associated with insulin resistance and diabetes mellitus: the Veterans Affairs HDL Intervention Trial (VA-HIT)," Atherosclerosis, Vol. 187, no. 1, pp. 153-160, 2006.
197. A. Keech, R. J. Simes, P. Barter, et al, "Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial," The Lancet, Vol. 366, no. 9500, pp. 1849-1861, 2005.
198. B. Staels and J.-C. Fruchart, "Therapeutic roles of peroxisome proliferator-activated receptor agonists," Diabetes, Vol. 54, no. 8, pp. 2460-2470, 2005.
199. F. Blaschke, Y. Takata, E. Caglayan, R. E. Law, and W. A. Hsueh, "Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes," Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 26, no. 1, pp. 28-40, 2006.
200. P. Biswas, L. V. Wilton, and S. A. Shakir, "Troglitazone and liver function abnormalities: lessons from a prescription event monitoring study and spontaneous reporting," Drug Safety, Vol. 24, no. 2, pp. 149-154, 2001.
201. "Troglitazone withdrawn from market," American Journal of Health-System Pharmacy, Vol. 57, no. 9, p. 834, 2000.
202. B. K. Irons, R. S. Greene, T. A. Mazzolini, K. L. Edwards, and R. B. Sleeper, "Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus," Pharmacotherapy, Vol. 26, no. 2, pp. 168-181, 2006.
203. J. A. Dormandy, B. Charbonnel, D. J. Eckland, et al, "Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial," The Lancet, Vol. 366, no. 9493, pp. 1279-1289, 2005.
204. S. M. Haffner, A. S. Greenberg, W. M. Weston, H. Chen, K. Williams, and M. I. Freed, "Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus," Circulation, Vol. 106, no. 6, pp. 679-684, 2002.
205. S. E. Kahn, S. M. Haffner, M. A. Heise, et al, "Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy," The New England Journal of Medicine, Vol. 355, no. 23, pp. 2427-2443, 2006.
206. A. J. Scheen, "DREAM study: prevention of type 2 diabetes with ramipril and/or rosiglitazone in persons with dysglycaemia but no cardiovascular desease," Revue Medicale de Liege, Vol. 61, no. 10, pp. 728-732, 2006.
207. P. D. Home, S. J. Pocock, H. Beck-Nielsen, et al, "Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis," The New England Journal of Medicine, Vol. 357, no. 1, pp. 28-38, 2007.
208. T.-A. Cock, S. M. Houten, and J. Auwerx, "Peroxisome proliferator-activated receptor-γ: too much of a good thing causes harm," EMBO Reports, Vol. 5, no. 2, pp. 142-147, 2004.
209. S. M. Rangwala and M. A. Lazar, "The dawn of the SPPARMs?" Science's STKE, Vol. 2002, no. 121, p. pe9, 2002.
210. P. V. Devasthale, S. Chen, Y. Jeon, et al, "Discovery of tertiary aminoacids as dual PPARα/γ agonists-I," Bioorganic & Medicinal Chemistry Letters, Vol. 17, no. 8, pp. 2312-2316, 2007.
211. P. V. Devasthale, S. Chen, Y Jeon, et al, "Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor α/γ dual agonist with efficacious glucose and lipid-lowering activities," Journal of Medicinal Chemistry, Vol. 48, no. 6, pp. 2248-2250, 2005.
212. T. Hatae, M. Wada, C. Yokoyama, M. Shimonishi, and T. Tanabe, "Prostacyclin-dependent apoptosis mediated by PPARδ," Journal of Biological Chemistry, Vol. 276, no. 49, pp. 46260-46267, 2001.
213. R. Hertz, I. Berman, D. Keppler, and J. Bar-Tana, "Activation of gene transcription by prostacyclin analogues is mediated by the peroxisome-proliferators-activated receptor (PPAR)," European Journal of Biochemistry, Vol. 235, no. 1-2, pp. 242-247, 1996.
214. H. Lim and S. K. Dey, "PPARδ functions as a prostacyclin receptor in blastocyst implantation," Trends in Endocrinology and Metabolism, Vol. 11, no. 4, pp. 137-142, 2000.